{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:59:16Z","timestamp":1770447556345,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12185-016-2158-0","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T11:21:58Z","timestamp":1480591318000},"page":"532-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment"],"prefix":"10.1007","volume":"105","author":[{"given":"Mariagrazia","family":"Porru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Mameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Cianchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Musu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Schirru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria F.","family":"Ruberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Barcellona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"2158_CR1","unstructured":"Boehringer Ingelheim. Pradaxa Summary of Product Characteristics. European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf . Accessed 18 May 2016"},{"key":"2158_CR2","doi-asserted-by":"crossref","unstructured":"Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. RE-LYinvestigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975\u201383.","DOI":"10.1016\/S0140-6736(10)61194-4"},{"key":"2158_CR3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel group, single-centre study. Clin Pharmacokinet. 2010;49:259\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"2158_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1076029611435840","volume":"18","author":"B Rochwerg","year":"2012","unstructured":"Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012;18:549\u201350.","journal-title":"Clin Appl Thromb Hemost"},{"key":"2158_CR5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J Ryn van","year":"2010","unstructured":"van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116\u201327.","journal-title":"Thromb Haemost"},{"key":"2158_CR6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","volume":"15","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2013;15:625\u201351.","journal-title":"Europace"},{"key":"2158_CR7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jth.12149","volume":"11","author":"T Baglin","year":"2013","unstructured":"Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756\u201360.","journal-title":"J Thromb Haemost"},{"key":"2158_CR8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511\u201320.","journal-title":"N Engl J Med"},{"key":"2158_CR9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386\u201399.","journal-title":"Drug Metab Dispos"},{"key":"2158_CR10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/15563650.2015.1004580","volume":"53","author":"J Bouchard","year":"2015","unstructured":"Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol (Phila). 2015;53:156\u201363.","journal-title":"Clin Toxicol (Phila)"},{"key":"2158_CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ckj\/sfv001","volume":"8","author":"G Claisse","year":"2015","unstructured":"Claisse G, Delavenne X, Masson I, Maillard N, Alamartine E, Mariat C. Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J. 2015;8:199\u2013201.","journal-title":"Clin Kidney J."},{"key":"2158_CR12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","volume":"61","author":"DN Chang","year":"2013","unstructured":"Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2158_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000381666","volume":"39","author":"F Artunc","year":"2015","unstructured":"Artunc F, Muehlbacher T, Baumann D, Birschmann I, Kuhn J, Heyne N, et al. Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis. Blood Purif. 2015;39:331\u20132.","journal-title":"Blood Purif"},{"key":"2158_CR14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","volume":"8","author":"T Singh","year":"2013","unstructured":"Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8:1533\u20139.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2158-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2158-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2158-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:59:03Z","timestamp":1498366743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2158-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2158-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}